Hoth Therapeutics
One Rockefeller Plaza
Suite 1039
New York
New York
10020
United States
Website: https://www.hoththerapeutics.com/
About Hoth Therapeutics
Hoth Therapeutics Inc. is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis.LEADERSHIP:
CEO: Robb Knie
185 articles about Hoth Therapeutics
-
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
-
Hoth Therapeutics Inc. Announces Completion of Series A Financing
2/22/2018
Hoth Therapeutics Inc. ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, announced today that it has completed its Series A financing totaling $3 million, before expenses, to fund operations and advance Hoth's BioLexa Platform.
-
Hoth Therapeutics Announces Issuance of First U.S. Patent on its BioLexa Platform
12/4/2017
The new patent is part of the technology portfolio Hoth is developing under an exclusive license from the UC.
-
Hoth Therapeutics Announces The Addition Of Dr. Richard D Granstein, M.D. To The Company's Technology Advisory Board
10/16/2017
Hoth Therapeutics announced today the addition of Dr. Richard D. Granstein, M.D., to the Company's Technology Advisory Board.
-
Hoth Therapeutics Announces The Addition Of Dr. Andrew Herr To The Company's Technology Advisory Board
9/5/2017